摘要
目标:流行病学数据表明非甾体类抗炎药(NSAIDs)可以预防阿尔茨海默病(AD)。不幸的是,最近的试验未能提供令人信服的神经保护证据。关于为什么NSAIDs有效性尚不确定的讨论正在进行中。可能的解释包括在患者出现AD或认知功能下降症状之前应提供NSAIDs和其他可能的疾病缓解药物。另外,用于神经保护的NSAID目标还不清楚。已提出COX依赖性和独立机制,包括裂解淀粉样蛋白前体蛋白(APP)并产生淀粉样蛋白β肽(Aβ)的γ-分泌酶。 方法:我们已经提出了基于抑制线粒体Ca 2+超载的NSAID的神经保护机制。 Aβ寡聚体促进Ca2 +内流和线粒体Ca2 +超载导致神经元细胞死亡。包括布洛芬,舒林酸,吲哚美辛和Rflurbiprofen在内的几种非特异性NSAIDs在低μM范围内使线粒体去极化,并防止由Aβ寡聚体和/或N-甲基-D-天冬氨酸(NMDA)诱导的线粒体Ca2 +超载。然而,在较高的浓度下,NSAIDs可能会破坏导致细胞死亡的线粒体潜能(ΔΨ)。 结果:因此,这种机制可能解释低浓度的神经保护作用和更大剂量的损伤,从而为有希望的试验的失败提供线索。对于将来的试验,应考虑降低NSAID浓度和/或具有较大动态范围的替代化合物以提供针对AD的神经保护的确切证据
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
Current Alzheimer Research
Title:Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Volume: 15 Issue: 6
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
摘要: Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ).
Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death.
Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Export Options
About this article
Cite this article as:
Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake, Current Alzheimer Research 2018; 15 (6) . https://dx.doi.org/10.2174/1567205015666171227154016
DOI https://dx.doi.org/10.2174/1567205015666171227154016 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Aorta Remodeling Due to Stretch or Turbulent Flow/Low Wall Shear Stress: Distinctly Different Biological Phenomena?
Current Cardiology Reviews The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research Multi-Nutrient Dietary Intervention Approach to the Management of Alzheimer’s Disease – A Mini-Review
Current Alzheimer Research Conference Report: 10th Clinical Trials on Alzheimer's Disease (CTAD), Boston MA, USA, November 1-4, 2017
CNS & Neurological Disorders - Drug Targets Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules
Current Pharmaceutical Design Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Bioorganic Compounds Produced by the Fungus Monascus and their Use in Health Sciences and Medicine
Mini-Reviews in Organic Chemistry Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Editorial: [Hot Topic HIV and Substance Abuse]
Current HIV Research The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design Immunophilins in Nervous System Degeneration and Regeneration
Current Topics in Medicinal Chemistry Potential Therapeutic Effects of Exogenous Ketone Supplementation for Type 2 Diabetes: A Review
Current Pharmaceutical Design